| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- JNJ-38877618
-
- $57.00
-
2026-07-27
- CAS:943540-74-7
- Purity: 99.74%
- Supply Ability: 10g
|
| | JNJ-38877605 Basic information |
| Product Name: | JNJ-38877605 | | Synonyms: | JNJ-38877618
(OMO1;OMO-1);6-(difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline;Quinoline, 6-[difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-;6-[Difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline;JNJ-38877618,Inhibitor,c-Met/HGFR,JNJ 38877618,JNJ38877618,inhibit;Venadaparib Impurity 21;JNJ-38877618, 10 mM in DMSO | | CAS: | 943540-74-7 | | MF: | C20H12F2N6 | | MW: | 374.35 | | EINECS: | | | Product Categories: | | | Mol File: | 943540-74-7.mol |  |
| | JNJ-38877605 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 5 mg/mL (13.36 mM) | | form | Solid | | color | White to off-white |
| | JNJ-38877605 Usage And Synthesis |
| Uses | JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. | | Biological Activity | JNJ-38877618 (OMO-1) is a potent, highly selective, and orally bioavailable Met (c-Met) kinase inhibitor with a Kd of 1.4 nM. Its IC50 values for wild-type Met (c-Met) and mutant Met (c-Met) (M1268T) were 2 nM and 3 nM, respectively. | | in vivo | In vivo, JNJ-38877618(OMO-1) completely inhibited tumor growth in 3 tumor models: SNU5 MET amp gastric cancer model, U87-MG HGF autocrine glioblastoma model, and exon 14 skipping deletion mutation Hs746T gastric cancer model of MET gene. Administration of OMO-1 in combination with other drugs is well tolerated and can improve and enhance the effect of EGFR-targeted therapy. Although single-agent OMO-1 has no effect on NSCLC HCC827 EGFR, its combination with erlotinib can delay tumor recurrence. | | target | | Target | Value | Met
(Cell-free assay) | 2 nM | MET (M1268T)
(Cell-free assay) | 3 nM | < /table>| References | [1] Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquire |
| | JNJ-38877605 Preparation Products And Raw materials |
|
|
Tag:JNJ-38877605(943540-74-7)
Related Product Information
|
|
FITC-Labeled HGFR Protein, Human (HEK293, His)
HGFR Protein, Rat (HEK293, Fc)
Foretinib (GSK1363089)
Savolitinib
Protein Tyrosine Kinase Compound Library
Anti-cancer compound library
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|